Application and validation of an advanced gastrointestinal in vitro model for the evaluation of drug product performance in pharmaceutical development

Journal of Pharmaceutical Sciences

Volumn 103, Issue 11, 2014, Pages 3704-3712

  Barker, Richard ^a   Abrahamsson, Bertil ^b   Kruusmägi, Martin ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Bioavailability; Dissolution; Formulation; In vitro in vivo correlations (IVIVC); Intestinal absorption; Physiological model; Poorly soluble drugs; Solubility; TIM 1; TNO

Indexed keywords

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; QUALITATIVE ANALYSIS; RISK ASSESSMENT; VALIDATION PROCESS; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DEVICES; DOG; EQUIPMENT DESIGN; INTESTINE; MEDICINAL CHEMISTRY; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PHYSIOLOGY; REPRODUCIBILITY; SOLUBILITY; STATISTICAL MODEL; STOMACH; VALIDATION STUDY;

DRUG;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DOGS; EQUIPMENT DESIGN; HUMANS; INTESTINES; LINEAR MODELS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; STOMACH; TECHNOLOGY, PHARMACEUTICAL;

EID: 84915748542     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24177     Document Type: Article

References (22)

1. Benet L, Wu C, Custodio J. 2006. Predicting drug absorption and the effects of food on oral bioavailability. Bull Techn Gattefosse 99:9-16.
2. Blanquet S, Zeijdner E, Beyssac E, Meunier JP, Denis S, Havenaar R, Alric M. 2004. A dynamic artificial gastrointestinal system for studying the behaviour of orally administered drug dosage forms under various physiological conditions. Pharm Res 21:585-591.
3. Ribnicky DM, Roopchand DE, Oren A, Grace M, Poulev A, Lila MA, Havenaar R, Raskin I. 2014. Effects of a high fat meal matrix and protein complexation on the bioaccessibility of blueberry anthocyanins using the TNO gastrointestinal model (TIM-1). Food Chem 142:349-357.
4. Souliman S, Blanquet S, Beyssac E, Cardot J-M. 2006. A level A in vitro/in vivo correlation in fasted and fed states using different methods: Applied to solid immediate release oral dosage form. Eur J Pharm Sci 27:72-79.
5. Cardot J-M, Beyssac E, Alric M. 2007. In vitro-in vivo correlation: Importance of dissolution in IVIVC. Diss Technol 14:15-19.
6. Dickinson PA, Ragheb AR, Lee A, Barker RA, Burke WM, Patterson CM, Stainforth N, Yasin M. 2012. An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs. AAPS J 14:196-205.
7. Sutton CS. 2004. Companion animal physiology and dosage form performance. Adv Drug Deliv Rev 56:1383-1398.
8. European Federation of Pharmaceutical Industries and Associations webpage. Animal welfare: 3R's - Replace, refine, reduce. Accessed, at: http://www.efpia.eu/documents/41/90/Animal-welfare-3R-39-s-Replace-Refine-Reducelast accesed September 9th, 2014
9. Agoram B, Woltosz, WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv 50:41-67.
10. Yu LX, Amidon GL. 1998. Saturable small intestinal drug absorption in humans: Modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm 45:199-203.
11. Sugano K. 2009. Computational oral absorption simulation for low-solubility compounds. Chem Biodivers 6:2014-2029.
12. Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, Abrahamsson B, Tannergren C. 2013. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim. Eur Jour Pharm Sci 49:679-698.
13. Garbacz G, Klein S. 2012. Dissolution testing of oral modified-release dosage forms. J Pharm Pharmacol 64:944-968.
14. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15:11-22.
15. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
16. Reis PM, Raab TW, Chuat JY, Leser ME, Miller R, Watzke HJ, Holmberg K. 2008. Influence of surfactants on lipase fat digestion in a model gastro-intestinal system. Food Biophys 3:370-381.
17. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products - General considerations. March 2003, Revision 1.
18. Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, Dickinson PA, Dressman J, Holm R, Klein S, Mann J, McAllister M, Minekus M, Muenster U, Müllertz A, Verwei M, Vertzoni M, Weitschies W, Augustijns P. 2014. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm 57:342-366.
19. Dickinson P, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, Hammett T, Billett L, Behn S, Gibb RC, Abrahamsson B. 2008. Clinical relevance of dissolution testing in quality by design. AAPS J 10:380-390.
20. Chiou WL, Jeong HY, Chung SM, Wu TC. 2000. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17:135-140.
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), ICH. 2006. Guidance for industry: Q8 pharmaceutical development.
22. Lennernäs H, Aarons L, Augustijns P, Beato S, Bolger M, Box K, Brewster M, Butler J, Dressman J, Holm R, Julia Frank K, Kendall R, Langguth P, Sydor J, Lindahl A, McAllister M, Muenster U, Müllertz A, Ojala K, Pepin X, Reppas C, Rostami-Hodjegan A, Verwei M, Weitschies W, Wilson C, Karlsson C, Abrahamsson B. 2014. Oral biopharmaceutics tools - Time for a new initiative - An introduction to the IMI project OrBiTo. Eur J Pharm Sci ]57:292-299.